FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2565235280> ?p ?o ?g. }

• W2565235280 abstract "Background: TAS-102 is a novel oral nucleoside antitumor agent composed of trifluridine (FTD) and tipiracil hydrochloride (TPI) at a molar ratio 1:0.5. FTD is the active antitumor component of TAS-102 and its triphosphate form is incorporated into DNA in tumor cells. TPI is a potent inhibitor of thymidine phosphorylase, an enzyme that degrades FTD, allowing adequate plasma concentrations of orally administered FTD to be maintained and potentiating the antitumor activity of FTD. In a recent international multicenter randomized double blind Phase III study (RECOURSE), use of TAS-102 was shown to significantly improve overall survival, progression-free survival and had a favorable safety profile in comparison to the placebo in patients with metastatic colorectal cancer refractory to standard chemotherapies. In this study, we evaluated the antitumor effects of TAS-102 in combination with oxaliplatin on gastrointestinal tumor xenografts, including a 5-FU-resistant subline, in a nude mouse model. Method: The human colorectal cell lines HCT-116 and SW48 and gastric cancer cell lines SC-2, MKN74 and MKN74/5-FU, a 5-FU-resistant cell line derived from MKN74, were implanted into nude mice subcutaneously. TAS-102 (150 mg/kg/day) was orally administered twice daily from days 1 to 14 and oxaliplatin (7 or 13 mg/kg/day) was administered intravenously on days 1 and 8. Growth inhibitory activity was evaluated by assessing tumor volume and the growth delay period, estimated based on the period required to reach a tumor volume five times greater than the initial volume (RTV5). Results: TAS-102 and oxaliplatin monotherapy were effective on all the evaluated colorectal and gastric cancers, even for a 5-FU-resistant gastric cancer cell line. The tumor growth inhibitory activity and RTV5 of the group receiving TAS-102 with oxaliplatin were significantly superior to those receiving either monotherapy for all evaluated cancers (P Citation Format: Mamoru Nukatsuka, Fumio Nakagawa, Kazuaki Matsuoka, Hiroshi Tsukihara, Teiji Takechi. Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, with oxaliplatin on human colorectal or gastric cancers and 5-FU-resistant gastric cancer xenografts. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 2557. doi:10.1158/1538-7445.AM2015-2557" @default.
• W2565235280 created "2017-01-06" @default.
• W2565235280 creator A5025498957 @default.
• W2565235280 creator A5050188027 @default.
• W2565235280 creator A5058238996 @default.
• W2565235280 creator A5063161716 @default.
• W2565235280 creator A5084347479 @default.
• W2565235280 date "2015-08-01" @default.
• W2565235280 modified "2023-09-27" @default.
• W2565235280 title "Abstract 2557: Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, with oxaliplatin on human colorectal or gastric cancers and 5-FU-resistant gastric cancer xenografts" @default.
• W2565235280 doi "https://doi.org/10.1158/1538-7445.am2015-2557" @default.
• W2565235280 hasPublicationYear "2015" @default.
• W2565235280 type Work @default.
• W2565235280 sameAs 2565235280 @default.
• W2565235280 citedByCount "0" @default.
• W2565235280 crossrefType "proceedings-article" @default.
• W2565235280 hasAuthorship W2565235280A5025498957 @default.
• W2565235280 hasAuthorship W2565235280A5050188027 @default.
• W2565235280 hasAuthorship W2565235280A5058238996 @default.
• W2565235280 hasAuthorship W2565235280A5063161716 @default.
• W2565235280 hasAuthorship W2565235280A5084347479 @default.
• W2565235280 hasConcept C121608353 @default.
• W2565235280 hasConcept C123321153 @default.
• W2565235280 hasConcept C126322002 @default.
• W2565235280 hasConcept C143998085 @default.
• W2565235280 hasConcept C2776694085 @default.
• W2565235280 hasConcept C2776735402 @default.
• W2565235280 hasConcept C2780456651 @default.
• W2565235280 hasConcept C2780962732 @default.
• W2565235280 hasConcept C502942594 @default.
• W2565235280 hasConcept C526805850 @default.
• W2565235280 hasConcept C71924100 @default.
• W2565235280 hasConcept C98274493 @default.
• W2565235280 hasConceptScore W2565235280C121608353 @default.
• W2565235280 hasConceptScore W2565235280C123321153 @default.
• W2565235280 hasConceptScore W2565235280C126322002 @default.
• W2565235280 hasConceptScore W2565235280C143998085 @default.
• W2565235280 hasConceptScore W2565235280C2776694085 @default.
• W2565235280 hasConceptScore W2565235280C2776735402 @default.
• W2565235280 hasConceptScore W2565235280C2780456651 @default.
• W2565235280 hasConceptScore W2565235280C2780962732 @default.
• W2565235280 hasConceptScore W2565235280C502942594 @default.
• W2565235280 hasConceptScore W2565235280C526805850 @default.
• W2565235280 hasConceptScore W2565235280C71924100 @default.
• W2565235280 hasConceptScore W2565235280C98274493 @default.
• W2565235280 hasLocation W25652352801 @default.
• W2565235280 hasOpenAccess W2565235280 @default.
• W2565235280 hasPrimaryLocation W25652352801 @default.
• W2565235280 isParatext "false" @default.
• W2565235280 isRetracted "false" @default.
• W2565235280 magId "2565235280" @default.
• W2565235280 workType "article" @default.